Trials / Recruiting
RecruitingNCT06748001
Avapritinib Rollover Study
An Open-label, Multicenter, Rollover Study in Patients Who Participated in an Avapritinib Clinical Study
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Blueprint Medicines Corporation · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avapritinib | Avapritinib will be administered in accordance with the parent study protocol. |
Timeline
- Start date
- 2024-11-28
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2024-12-24
- Last updated
- 2026-02-09
Locations
7 sites across 6 countries: Belgium, Canada, Italy, Netherlands, Norway, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06748001. Inclusion in this directory is not an endorsement.